Potential of epigenetic therapies in the management of solid tumors

Cancer Management and Research
Victor Valdespino, Patricia M Valdespino

Abstract

Cancer is a complex disease with both genetic and epigenetic origins. The growing field of epigenetics has contributed to our understanding of oncogenesis and tumor progression, and has allowed the development of novel therapeutic drugs. First-generation epigenetic inhibitor drugs have obtained modest clinical results in two types of hematological malignancy. Second-generation epigenetic inhibitors are in development, and have intrinsically greater selectivity for their molecular targets. Solid tumors are more genetic and epigenetically complex than hematological malignancies, but the transcriptome and epigenome biomarkers have been identified for many of these malignancies. This solid tumor molecular aberration profile may be modified using specific or quasi-specific epidrugs together with conventional and innovative anticancer treatments. In this critical review, we briefly analyze the strategies to select the targeted epigenetic changes, enumerate the second-generation epigenetic inhibitors, and describe the main signs indicating the potential of epigenetic therapies in the management of solid tumors. We also highlight the work of consortia or academic organizations that support the undertaking of human epigenetic therapeuti...Continue Reading

Citations

Dec 5, 2015·Expert Review of Molecular Diagnostics·Akihiro NishiShuji Ogino
Apr 28, 2016·Scientifica·Dipanjan BhattacharjeeKurady Laxminarayana Bairy
May 4, 2017·Expert Opinion on Therapeutic Patents·Prashant S Kharkar
Jun 26, 2018·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Anastas PashovThomas Kieber-Emmons
Apr 2, 2019·Expert Opinion on Biological Therapy·Youngwoo ChoMansoor M Amiji
Feb 6, 2020·Cancers·Hélène LossonMarc Diederich
May 19, 2017·Oncotarget·Adrien MorelJean-Luc Prétet
Sep 10, 2017·Journal of Cellular Physiology·Narges SoozangarNasser Samadi
Dec 14, 2018·Molecular Diagnosis & Therapy·Katarzyna KamińskaMarzena Anna Lewandowska
Oct 5, 2019·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Yehuda G AssarafM Helena Vasconcelos
Nov 6, 2020·International Journal of Molecular Sciences·Kasturi RangannaZivar Yousefipour
Mar 27, 2021·Seminars in Cancer Biology·Manoj SinghAnil K Sharma
Nov 6, 2018·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Colin R YoungEsther Mena

❮ Previous
Next ❯

Methods Mentioned

BETA
CHIP-Chip
histone acetylation
acetylation
deamination
biopsies

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

Journal of Mammary Gland Biology and Neoplasia
Roisin Connolly, Vered Stearns
Clinical & Experimental Metastasis
Kelly T Huynh, Dave S B Hoon
© 2021 Meta ULC. All rights reserved